Cara Therapeutic Stock Performance
| CARA Stock | USD 5.12 0.08 1.59% |
On a scale of 0 to 100, Cara Therapeutic holds a performance score of 6. The firm shows a Beta (market volatility) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cara Therapeutic will likely underperform. Please check Cara Therapeutic's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Cara Therapeutic's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cara Therapeutic are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Cara Therapeutic sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 64.1 M |
Cara |
Cara Therapeutic Relative Risk vs. Return Landscape
If you would invest 409.00 in Cara Therapeutic on November 9, 2024 and sell it today you would earn a total of 103.00 from holding Cara Therapeutic or generate 25.18% return on investment over 90 days. Cara Therapeutic is currently generating 0.8407% in daily expected returns and assumes 10.676% risk (volatility on return distribution) over the 90 days horizon. In different words, 95% of stocks are less volatile than Cara, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cara Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cara Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cara Therapeutic, and traders can use it to determine the average amount a Cara Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0787
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CARA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.68 actual daily | 95 95% of assets are less volatile |
Expected Return
| 0.84 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cara Therapeutic is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cara Therapeutic by adding it to a well-diversified portfolio.
Cara Therapeutic Fundamentals Growth
Cara Stock prices reflect investors' perceptions of the future prospects and financial health of Cara Therapeutic, and Cara Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cara Stock performance.
| Return On Equity | -1.84 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (16.36) % | ||||
| Current Valuation | (15.58 M) | ||||
| Shares Outstanding | 4.57 M | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 32.59 X | ||||
| Price To Sales | 2.10 X | ||||
| Revenue | 20.97 M | ||||
| EBITDA | (117.65 M) | ||||
| Cash And Equivalents | 157.51 M | ||||
| Cash Per Share | 2.93 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (92.08 M) | ||||
| Earnings Per Share | (21.00) X | ||||
| Total Asset | 125.84 M | ||||
| Retained Earnings | (684.75 M) | ||||
| Current Asset | 108.93 M | ||||
| Current Liabilities | 5.27 M | ||||
About Cara Therapeutic Performance
By analyzing Cara Therapeutic's fundamental ratios, stakeholders can gain valuable insights into Cara Therapeutic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cara Therapeutic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cara Therapeutic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.Things to note about Cara Therapeutic performance evaluation
Checking the ongoing alerts about Cara Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cara Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cara Therapeutic is way too risky over 90 days horizon | |
| Cara Therapeutic appears to be risky and price may revert if volatility continues | |
| Cara Therapeutic has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (77.85 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93. | |
| Roughly 16.0% of the company shares are held by company insiders |
- Analyzing Cara Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cara Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Cara Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cara Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cara Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cara Therapeutic's stock. These opinions can provide insight into Cara Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |